» Articles » PMID: 29247070

Mixed-location Cerebral Hemorrhage/microbleeds: Underlying Microangiopathy and Recurrence Risk

Overview
Journal Neurology
Specialty Neurology
Date 2017 Dec 17
PMID 29247070
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the predominant type of cerebral small vessel disease (SVD) and recurrence risk in patients who present with a combination of lobar and deep intracerebral hemorrhage (ICH)/microbleed locations (mixed ICH).

Methods: Of 391 consecutive patients with primary ICH enrolled in a prospective registry, 75 (19%) had mixed ICH. Their demographics, clinical/laboratory features, and SVD neuroimaging markers were compared to those of 191 patients with probable cerebral amyloid angiopathy (CAA-ICH) and 125 with hypertensive strictly deep microbleeds and ICH (HTN-ICH). ICH recurrence and case fatality were also analyzed.

Results: Patients with mixed ICH showed a higher burden of vascular risk factors reflected by a higher rate of left ventricular hypertrophy, higher creatinine values, and more lacunes and severe basal ganglia (BG) enlarged perivascular spaces (EPVS) than patients with CAA-ICH (all < 0.05). In multivariable models mixed ICH diagnosis was associated with higher creatinine levels (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.2-5.0, = 0.010), more lacunes (OR 3.4, 95% CI 1.7-6.8), and more severe BG EPVS (OR 5.8, 95% CI 1.7-19.7) than patients with CAA-ICH. Conversely, when patients with mixed ICH were compared to patients with HTN-ICH, they were independently associated with older age (OR 1.03, 95% CI 1.02-1.1), more lacunes (OR 2.4, 95% CI 1.1-5.3), and higher microbleed count (OR 1.6, 95% CI 1.3-2.0). Among 90-day survivors, adjusted case fatality rates were similar for all 3 categories. Annual risk of ICH recurrence was 5.1% for mixed ICH, higher than for HTN-ICH but lower than for CAA-ICH (1.6% and 10.4%, respectively).

Conclusions: Mixed ICH, commonly seen on MRI obtained during etiologic workup, appears to be driven mostly by vascular risk factors similar to HTN-ICH but demonstrates more severe parenchymal damage and higher ICH recurrence risk.

Citing Articles

Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy.

Hsieh P, Tsai H, Liu C, Lee B, Tsai Y, Yen R Eur J Neurol. 2025; 32(2):e70066.

PMID: 39907306 PMC: 11795418. DOI: 10.1111/ene.70066.


Characterizing the underlying microangiopathy of deep cerebellar intracerebral hemorrhage.

Das A, Abramovitz Fouks A, Gokcal E, Rotschild O, Pasi M, Regenhardt R J Neurol. 2025; 272(2):167.

PMID: 39853492 DOI: 10.1007/s00415-025-12905-8.


Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know.

Tanaka F, Maeda M, Kishi S, Kogue R, Umino M, Ishikawa H Jpn J Radiol. 2024; .

PMID: 39730931 DOI: 10.1007/s11604-024-01720-2.


Association of social vulnerability and depression incidence post intracerebral haemorrhage: a cohort study.

Popescu D, Abramson J, Keins S, Mallick A, Kourkoulis C, Anderson C BMJ Neurol Open. 2024; 6(2):e000728.

PMID: 39720508 PMC: 11667396. DOI: 10.1136/bmjno-2024-000728.


Tension at the gate: sensing mechanical forces at the blood-brain barrier in health and disease.

Hansen C, Hollaus D, Kamermans A, de Vries H J Neuroinflammation. 2024; 21(1):325.

PMID: 39696463 PMC: 11657007. DOI: 10.1186/s12974-024-03321-2.


References
1.
Gurol M . Molecular Neuroimaging in Vascular Cognitive Impairment. Stroke. 2016; 47(4):1146-52. DOI: 10.1161/STROKEAHA.115.007958. View

2.
Gurol M, Irizarry M, Smith E, Raju S, Diaz-Arrastia R, Bottiglieri T . Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006; 66(1):23-9. DOI: 10.1212/01.wnl.0000191403.95453.6a. View

3.
Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R . Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999; 20(4):637-42. PMC: 7056037. View

4.
Pantoni L . Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9(7):689-701. DOI: 10.1016/S1474-4422(10)70104-6. View

5.
Pasi M, Boulouis G, Fotiadis P, Auriel E, Charidimou A, Haley K . Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease. Neurology. 2017; 88(23):2162-2168. PMC: 5467956. DOI: 10.1212/WNL.0000000000004007. View